Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Eli Lilly & Co. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Eli Lilly & Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The solvency profile exhibits a cyclical trajectory characterized by a period of increasing financial leverage and debt reliance that peaked between late 2023 and early 2025, followed by a marked trend toward deleveraging and improved solvency positions by the first quarter of 2026.
- Debt to Equity Ratio
- The ratio demonstrates a steady climb from 1.77 in March 2022 to a peak of 2.44 in March 2025. This upward trajectory indicates an increasing reliance on debt relative to shareholder equity over a three-year period. However, a significant reversal is observed following this peak, with the ratio declining sharply to 1.39 by March 2026, suggesting a substantial reduction in debt or a significant increase in equity.
- Debt to Capital Ratio
- A similar pattern is observed in the debt to capital ratio, which remained relatively stable between 0.60 and 0.64 throughout 2022 before rising to a high of 0.71 in March 2025. The subsequent decline to 0.58 by March 2026 reflects a strategic shift in the capital structure, reducing the proportion of total capital financed through debt.
- Debt to Assets Ratio
- The debt to assets ratio shows a gradual increase from 0.35 in March 2022 to a maximum of 0.43 between December 2024 and March 2025. This indicates that a larger portion of the company's assets were financed by debt during this interval. By March 2026, the ratio moderated to 0.37, signaling a return toward baseline asset-financing levels.
- Financial Leverage
- Financial leverage exhibited the most volatility, peaking at 5.94 in December 2023 and remaining elevated above 5.00 through much of 2024 and early 2025. A rapid contraction is observed in the final year of the period, with leverage dropping to 3.74 by March 2026. This represents the lowest leverage level across the entire analyzed timeframe, indicating a significant strengthening of the balance sheet.
Overall, the solvency indicators suggest a strategic expansion of debt-funded activities peaking in early 2025, followed by a concerted effort to reduce financial risk and optimize the capital structure through 2026.
Debt Ratios
Debt to Equity
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Short-term borrowings and current maturities of long-term debt | |||||||||||||||||||||||
| Long-term debt, excluding current maturities | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Total Eli Lilly and Company shareholders’ equity | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Debt to equity = Total debt ÷ Total Eli Lilly and Company shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The solvency profile reveals a period of significant expansion in both total liabilities and shareholders' equity, characterized by a cyclical movement in leverage. Total debt increased from US$ 16,509 million in March 2022 to US$ 43,370 million by March 2026, reflecting a substantial growth in the company's borrowing. Concurrently, shareholders' equity rose from US$ 9,331 million to US$ 31,198 million over the same period.
- Debt Accumulation and Leverage Peak
- A steady increase in leverage is observed from late 2022 through the end of 2024. During this phase, the debt-to-equity ratio climbed from 1.52 in December 2022 to a peak of 2.37 in December 2024. This trend indicates a period where debt growth outpaced the accumulation of equity, increasing the company's financial leverage.
- Equity Acceleration and Deleveraging
- Starting in March 2025, a pivot in the solvency trend occurred. Although total debt continued to rise in absolute terms, shareholders' equity grew at a significantly faster rate, surging from US$ 15,765 million in December 2024 to US$ 31,198 million by March 2026. This aggressive growth in the equity base resulted in a sharp contraction of the debt-to-equity ratio.
- Final Solvency Position
- By March 31, 2026, the debt-to-equity ratio reached 1.39, the lowest level recorded across the entire analyzed timeframe. This trajectory demonstrates that while the company maintains a higher absolute debt load than in 2022, its solvency position has strengthened significantly due to a robust increase in equity capitalization.
Debt to Capital
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Short-term borrowings and current maturities of long-term debt | |||||||||||||||||||||||
| Long-term debt, excluding current maturities | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Total Eli Lilly and Company shareholders’ equity | |||||||||||||||||||||||
| Total capital | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
An analysis of the solvency trajectory reveals a period of expanding leverage followed by a projected deleveraging phase. While both total debt and total capital exhibited consistent growth over the analyzed period, the proportion of debt relative to total capital shifted through three distinct phases.
- Initial Stability Period (March 2022 – September 2023)
- The debt to capital ratio remained relatively stable, fluctuating within a narrow range between 0.60 and 0.66. During this interval, total debt grew modestly from 16,509 million to 20,168 million, while total capital increased from 25,840 million to 31,389 million, maintaining a consistent balance in the capital structure.
- Leverage Expansion (December 2023 – March 2025)
- A notable increase in the debt to capital ratio is observed, peaking at 0.71 in March 2025. This trend was driven by an acceleration in total debt, which rose sharply from 20,168 million in September 2023 to 38,516 million by March 2025. During this phase, the growth in debt obligations outpaced the growth in total capital, leading to a higher proportional reliance on borrowed funds.
- Projected Deleveraging (June 2025 – March 2026)
- A consistent downward trend in the debt to capital ratio occurs in the final quarters, descending to 0.58 by March 2026. This improvement in the solvency ratio persists despite total debt continuing to rise to 43,370 million. The reduction is attributable to a significant expansion of total capital, which reached 74,568 million, effectively diluting the weight of debt within the overall capital structure.
Debt to Assets
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Short-term borrowings and current maturities of long-term debt | |||||||||||||||||||||||
| Long-term debt, excluding current maturities | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The solvency profile reflects a period of aggressive balance sheet expansion characterized by a simultaneous and substantial increase in both total debt and total assets from March 2022 through March 2026.
- Total Debt Trajectory
- A consistent upward trend in total debt is observed, with obligations rising from 16,509 million US$ in March 2022 to 43,370 million US$ by March 2026. The most significant acceleration in debt accumulation occurred between December 2023 and December 2024, during which total debt increased from 25,225 million US$ to 33,644 million US$.
- Total Asset Expansion
- Total assets grew more than twofold over the analyzed period, increasing from 46,919 million US$ in March 2022 to 116,576 million US$ by March 2026. A period of rapid asset growth is particularly evident between December 2024 and September 2025, where assets expanded from 78,715 million US$ to a peak of 114,935 million US$.
- Debt to Assets Ratio Analysis
- The debt to assets ratio exhibited three distinct phases. First, a period of stability was maintained throughout 2022, with the ratio fluctuating narrowly between 0.33 and 0.36. Second, a gradual increase in leverage occurred from March 2023 through December 2024, reaching a peak ratio of 0.43. Third, a deleveraging trend is observed from January 2025 onward, as the ratio declined to 0.37 by March 2026. This final phase indicates that asset growth significantly outpaced the acquisition of new debt, improving the overall solvency position.
Financial Leverage
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Total Eli Lilly and Company shareholders’ equity | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Financial leverage = Total assets ÷ Total Eli Lilly and Company shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
An examination of the balance sheet indicates a period of significant asset expansion coupled with a strategic shift in financial leverage. Total assets grew consistently from 46,919 million USD in March 2022 to 116,576 million USD by March 2026, representing a substantial increase in the company's resource base over the analyzed timeframe.
- Total Asset Growth
- Asset accumulation showed steady growth through 2022 and 2023, followed by a more rapid acceleration throughout 2024 and 2025. A particularly pronounced increase is observed between March 2025 and September 2025, where assets rose from 89,389 million USD to 114,935 million USD.
- Shareholders' Equity Trends
- Equity levels remained relatively stable between March 2022 and December 2023, fluctuating between 8,545 million USD and 11,220 million USD. A strong upward trajectory began in 2024 and accelerated sharply throughout 2025, culminating in a value of 31,198 million USD by March 2026, suggesting a significant strengthening of the company's internal funding and net worth.
- Financial Leverage Dynamics
- The financial leverage ratio exhibited a period of increase and instability early in the sequence, peaking at 5.94 in December 2023. While the ratio remained elevated through the first half of 2024, a definitive deleveraging trend emerged starting in June 2025. The ratio declined steadily from 5.52 in June 2025 to a period low of 3.74 by March 2026, indicating a shift toward a more conservative capital structure and a reduced reliance on debt relative to equity.